VANCOUVER, British Columbia, Oct. 10, 2018 — Veritas Pharma Inc. (CSE: VRT; OTC: VRTHF; and Frankfurt: 2VP) (“Veritas” or the “Company”) is pleased to announce that Cannevert Therapeutics Ltd.’s (“Cannevert”) Director of Regulatory Affairs and Quality Assurance, Dr. Andrew Hegle has been selected to attend the 7th Annual Masterclass Medicinal Cannabis in Ottawa, Ontario from October 28 to November 2, 2018.
The Masterclass Medicinal Cannabis® is an exclusive education seminar hosted by Dr. Arno Hazekamp, the former Head of Research and Education for Bedrocan BV, a multinational company that has been growing and supplying pharmaceutical grade medicinal cannabis since the early 1980s. Since its start in 2011, the Masterclass has provided a one week intensive and in-depth learning environment focused on providing science-based information on all aspects of cannabis as a plant-based medicine. The program is designed to educate individuals from all walks of life, including patients, politicians, advocates, scientists, business, physicians, and ancillary services to the industry.
This year marks the first time the Masterclass has been held outside of the Netherlands, and comes at the heels of Federal legalization in Canada, making it the first G7 nation to fully legalize cannabis. Masterclass 2018 will be held in cooperation with Canopy Growth, an international and widely diversified Licensed Cannabis Producer headquartered in Canada. Masterclass participants will have the opportunity to visit their state-of-the-art facilities in Smith Falls, Ontario during the final day of the course.
Veritas CEO, Dr. Lui Franciosi, stated that “We are pleased to have Cannevert represented again at this event. Bedrocan continues to have an interest in Cannevert’s scientific approach of using functional techniques to assess the potential of whole plant extracts for specific disease conditions. It will give Andrew an opportunity to learn and contribute to the best practices in the medicinal cannabis industry.”
About Veritas Pharma Inc. Veritas Pharma Inc. is an emerging pharmaceutical and IP development company, who, through its 100% owned subsidiary Cannevert Therapeutics Ltd. (“CTL“), is advancing the science behind medical cannabis. It is the Company’s aim, through its investment in CTL, to develop the most effective cannabis strains (cultivars) specific to pain, nausea, epilepsy and PTSD, solving the critical need for clinical data to support medical marijuana claims. CTL’s unique value proposition uses a low-cost research and development model to help drive shareholder value, and speed-to-market. Veritas’ investment in CTL is led by a strong management team, bringing together veteran academic pharmacologists, anesthetists & chemists. The company’s commercial mission is to patent protect IP (cultivars & strains) and sell or license to cancer clinics, insurance industry and pharma, targeting multi-billion-dollar markets according to Deloitte’s Insights and Opportunities.
WANT TO BUILD A FINANCIAL EMPIRE?
Subscribe to the Global Banking & Finance Review Newsletter for FREE Get Access to Exclusive Reports to Save Time & Money
By using this form you agree with the storage and handling of your data by this website. We Will Not Spam, Rent, or Sell Your Information.
Veritas Pharma Inc. is a publicly traded company in Canada, on the Canadian Stock Exchange under the ticker VRT; in the United States, on the OTC under the ticker VRTHF; and in Germany, on the Frankfurt exchange under the ticker 2VP.
For more information, please visit our website: veritaspharmainc.com
On behalf of the Board of Directors
“Dr. Lui Franciosi” Dr. Lui Franciosi President and Chief Executive Officer
Further information about the Company is available on our website at www.veritaspharmainc.com or under our profile on SEDAR at www.sedar.com and on the CSE website at www.thecse.com.
Investor and Public Relations Contact Veritas Pharma Inc. Sam Eskandari Telephone: +1.416.918.6785 Email: [email protected] Website: www.veritaspharmainc.com
The CSE has not reviewed, nor approved or disapproved the content of this press release.